Annual Securities Report — FY2025
What PhoenixBio Co.,Ltd. reported for the period from 2025-04-01 to 2026-03-31. Filed by 株式会社フェニックスバイオ
Filed 2026-06-25View the original on EDINET
How much it says
52Typical
What moved here
15named for the first time
Its own wording
48terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the fiscal year, overseas markets struggled because overseas pharmaceutical companies reduced their development budgets, while increased repeat use of PXB mice in Japan kept revenue broadly in line with the previous year. On the earnings front, the dissolution and liquidation of KMT Hepatech, Inc., the consolidated subsidiary that operated the overseas production facility, improved the breakeven point and brought the group into operating profitability.
Komori's summary of this document, not the document's own words.52Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
84
Very detailed
45
Typical
60
Detailed
62
Detailed
25
Almost nothing
15
Almost nothing
68
Detailed
71
Detailed
7
Almost nothing
79
Very detailed
50
Typical
R&D spend2億円Money spent making new things.
Cash left over55百万円Cash from the business, less what went into equipment.
Spent on equipment30百万円Plants, machines — things meant to last.
Employees55Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.